IRVING, Texas, Feb. 21, 2014 /PRNewswire/ -- Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine, today announced that former President George W. Bush, the 43rd President of the United States, was the featured keynote speaker at its annual sales meeting held in Phoenix, Ariz., this week. President Bush's remarks were featured as part of a conversation between the President and David D. Halbert, Chairman and CEO of Caris Life Sciences.
"I'm pleased to have the opportunity to speak with the folks here at Caris who are doing such important work for cancer patients around the world," said President Bush. "The company's leadership has also been a valued partner in our Pink Ribbon Red Ribbon® Initiative, where we have provided desperately-needed medical relief in Africa and other areas of need."
The President's remarks focused primarily on his thoughts about leadership during times of great challenge. Topics included the September 11 terrorist attacks, the financial crisis of 2008 and foreign policy issues he faced during his presidency. He also spoke about his and former First Lady Laura Bush's work in Africa and other developing nations during the past five years to provide medical care and services for HIV/AIDS, cervical cancer, malaria and tuberculosis, including the Pink Ribbon Red Ribbon® Initiative, in which the Caris Foundation is a partner.
"It was an honor to host President Bush, someone who holds such a unique, pivotal place in our nation's history, as a guest and keynote speaker at Caris' recent annual meeting," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "The President's candid reflections on the meaning and ultimate responsibility of leadership, as well as his obvious passion for providing medical relief in places of great suffering around the world, were thought-provoking and inspiring."
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. As the first commercial mover in comprehensive molecular profiling in oncology, Caris Molecular Intelligence™ is an industry vanguard, with 60,000-plus patients profiled and counting. Ordered by nearly 6,000 oncologists in 59 countries, Molecular Intelligence correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from clinical cancer literature. Using a variety of advanced and clinically-relevant technologies, Caris provides oncologists with the most clinically actionable information to help them personalize treatment for cancer patients. This multi-technology approach enables Caris to provide therapeutic guidance for 43 drug associations, compared to the 12 that can be found through use of next-generation sequencing alone. The company is also developing a series of blood tests based on its proprietary Carisome® platform — a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.
SOURCE Caris Life Sciences